Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II

The development of immune checkpoint inhibitors (ICIs) has changed the treatment paradigm for cancer. The ICIs nivolumab, pembrolizumab, and cemiplimab target programmed cell death protein 1, and durvalumab, avelumab, and atezolizumab target programmed death ligand 1. Ipilimumab targets cytotoxic T...

Descripción completa

Detalles Bibliográficos
Autores principales: Bukamur, Hazim, Alkrekshi, Akram, Katz, Heather, Alsharedi, Mohamed, Shweihat, Yousef R., Munn, Nancy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Medicine & Medical Specialties
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389348/
https://www.ncbi.nlm.nih.gov/pubmed/34480197
http://dx.doi.org/10.14423/SMJ.0000000000001295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389348/
https://www.ncbi.nlm.nih.gov/pubmed/34480197
http://dx.doi.org/10.14423/SMJ.0000000000001295

Ejemplares similares